Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью
________________________________________________
Aliyeva A.M., Baykova I.E., Kislyakov V.A., et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Therapeutic Archive. 2019; 91 (9): 145–149. DOI: 10.26442/00403660.2019.09.000226
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: галектин-3, биомаркер, хроническая сердечная недостаточность, сердечно-сосудистые заболевания, ремоделирование миокарда.
________________________________________________
Now there is a relevant development of the new biomarkers capable to serve as the instrument of early diagnostics of a disease for the purpose of selection of a pharmacotherapy and further monitoring of its efficiency. Galektin-3 is the atypical representative of the family of galektin. Its participation in fibrosis, remodeling of heart, the immunologic answer and inflammatory reactions are shown. Prognostic value is discussed and diagnostic opportunities of Galektin-3 at CHF are widely studied and take root into clinical practice. Now a great deal of research devoted to the studying of Galektin-3, possibilities of its use as a biomarker at diagnostics, forecasting of outcomes and the choice of therapeutic strategy at other cardiovascular diseases has been conducted.
Keywords: galektin-3, biomarker, chronic heart failure, cardiovascular diseases, remodeling of a myocardium.
2. Сергеева Е.М., Малишевский М.В., Васина А.А., Мищенко Т.А., Кузьмина Ю.С., Раемгулов Р.А. Лечение хронической сердечной недостаточности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и образование Урала. 2015;16(4):32-4 [Sergeeva EM, Malishevskiy MV, Vasina AA, Mishenko TA, Kuzmina YuS, Raemgulov RA. Treatment of chronic heart failure in primary health care in Tyumen. Medical science and education of the Urals. 2015;16(4):32-4 (In Russ.)].
3. Кириллова В.В. Ремоделирование миокарда у пациентов с фибрилляцией предсердий при хронической сердечной недостаточности. Трансляционная медицина. 2018;5(2):15-21 [Kirillova VV. Remodeling of a myocardium at patients with fibrillation of auricles at a chronic heart failure. Transmitting medicine. 2018;5(2):15-21 (In Russ.)]. doi:10.18705/2311-4495-2018-5-2-15-21
4. Мареев В.Ю. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности. М., 2016:92 [Mareev VYu, et al. Clinical recommendations for Chronic heart failure (CHF). Society for Heart Failure Specialists. Moscow, 2016:92 (In Russ.)].
5. Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1093/eurheartj/ehw 128
6. Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1-20. doi:10.1016/j. jchf.2012.10.002
7. Алиева А.М., Резник Е.В., Гасанова Э.Т., Жбанов И.В., Никитин И.Г. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45 [Aliyeva AM, Reznik EV, Gasanova ET, Zhbanov IV, Nikitin IG. Clinical value of definition of biomarkers of a blood at patients with a chronic heart failure. Archive of internal medicine. 2018;8(5):333-45 (In Russ.)]. doi:10. 20514/ 2226-6704-2018-8-5-333-345
8. Агеев Ф.Т., Азизова А. Г. Галектин-3 – новый биохимический маркер сердечной недостаточности. Сердечная Недостаточность. 2011;12 (2):108-14 [Ageev FT, Azizova AG. Galektin-3 – a new biochemical marker of a heart failure. J Heart Failure. 2011;12 (2):108-14 (In Russ.)].
9. Драпкина О.М., Деева Т.А. Галектин-3 – биомаркер фиброза у пациентов с метаболическим синдромом. Российский кардиологический журнал. 2015;(9):96-102 [ Drapkina OM, Deyeva TA. Galektin-3 – a fibrosis biomarker at patients with a metabolic syndrome. Russian cardiologic journal. 2015;(9):96-102 (In Russ.)]. doi:10.15829/1560-4071-2015-9-96-102
10. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Research Reports in Clinical Cardiology. 2013:4:13-2. doi:10.21 47/rrcc.s28562
11. de Filippi CR, Felker GM. Galectin-3 in heart failure-linking fibrosis, remodeling, and progression. US Cardiology. 2010;7(1):67-70. doi:10.15420/ ecr.2010.6.2.33
12. Billebeau G, Vodovar N, et al. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Cohen-SolalA. Eur J Prev Cardiol. 2017;24(11):1127-35. doi:10.1177%2F204748731 7705488
13. Гямджян К.А. Роль галектина-3 в диагностике и контроле за лечением пациентов с хронической сердечной недостаточностью, сопоставление с NT-PROBNP: дисс…. канд. мед. наук. М., 2017:120 с. [Gyamyagyan KA. The role of galectin-3 in the diagnosis and control of treatment of patients with chronic heart failure, comparison with NT-PROBNP: Thesis for the degree of candidate of medical Sciences. Moscow, 2017:120 p (In Russ.)].
14. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal ProBNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiology. 2005;95(8):948-54. doi:10.1016/j.cardfail.2005.04.011
15. Felker G, Fiuzat M, Shaw M, et al. Galectin-3 in ambulatory patients with heart failure results from the HF-ACTION study. Circulation: Heart Failure. 2012;5(1):72-8. doi:10.1161/circheartfailure.111.963637
16. Felker G, Whellan D, Kraus W, et al. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: Data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. Am Heart J. 2009;158. doi:10.1016/j.ahj.2009.07.011
17. Дуболазова Ю.В., Драпкина О.М. Применение галектина-3 и NT-PROBNP в качестве биомаркеров декомпенсированной сердечной недостаточности. Российский кардиологический журнал. 2017;(1):95-101 [Dubolazova YV, Drapkina OM. Application of galectin-3 and NT-PROBNP as biomarkers of decompensated heart failure. Russian cardiology journal. 2017;(1):95-101 (In Russ.)]. doi:10.15829/1560-4071-2017-1-95-101
18. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in apo E-deficient mice. Am J Pathol. 2008;172:247-55. doi:10.2353/ajpath.2008.070348
19. Лакомкин С.В., Скворцов А.А., Горюнова Т.В., Масенкова В.П., Терещенко С.Н. Галектин-3 – новый маркер диагностики и прогноза хронической сердечной недостаточности. Кардиология. 2012;(3):45-52 [Lakomkin SV, Skvortsov AA, Goryunova TV, Masenko VP, Tereshchenko SN. Galektin-3 — a new marker of diagnostics and the forecast of a chronic heart failure. Cardiology. 2012;(3): 45-52 (In Russ.)].
20. Целуйко З.С., Вашакидзе Т.В.,Mотылевская Н.А., ОполонскаяВ.И. Галектин-3 у больных с фибрилляцией предсердий. Украинский кардиологический журнал. 2012;(3):45-9 [Tseluyko ZS, Vashakidze TV, Motylevskaya, NA, Opolonskaya VI. Galektin-3 at patients with fibrillation of auricles. The Ukrainian cardiologic journal. 2012;(3):45-9 (In Russ.)].
21. Lok DJA, Van Der Meer P, de la Porte PWB-A, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clinical Research in Cardiology: Official Journal of the German Cardiac Society. 2010;99(5):323-8. doi:10.1007/s00392-010-0125-y
22. Щукин Ю. В., Березин И.И., Медведева Е.А., Селезнев Е.И., Дьячков В.А. O значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительнo-нитрозилирующего стресса у бoльных хрoнической сердечной недoстаточностью. Рoссийский кардиoлогический журнал. 2013;2(100):45-9 [Shukin YuV, Seleznev EI, Berezin EE, Medvedeva EA, Djachkov VA. The connection of plаzma сontents of gаlectin-3 with mаrkers of oxidative and nitrosylаte stresses of patients with chronic heart failure. Russ J Сardiol. 2013;2(100):45-9 (In Russ.)]. doi:10.15829/1560-4071-2013-2-45-49
23. Lin YH, Ho YL, Wаng TD, et al. The relation of amino-terminal propeptide of type III procollаgen and severity of coronаry аrtery disease in patients without myocardial infarction or hibernаtion. Clin Biоchem. 2006;39:861-6. doi:10.1016/ j.clinbiochem.2006.05.017
24. Lin YH, Shiau YC, Yen RF, et al. The relаtion between myocardial cyclic variation of integrated backscatter and serum concentrations of procollаgen propeptides in hypertensive patients. Ultrasound Med Biol. 2004;30:885-91. doi:10.1016/j.ultrasmedbio.2004.04.007
25. Lombаrdi R, Betocchi S, Losi MA, et al. Myocаrdial collаgen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108:1455-60. doi:10.1161/01. cir.0000090687.97972.10
26. Rossi A, Cicoira M, Goliа G, et al. Amino-terminal propeptide of type III procollаgen is аssociated with restrictive mitral filling pattern in patients with dilаted cаrdiomyopathy: а possible link between diаstolic dysfunction and prognosis. Heаrt. 2004;90:650-4. doi:10.1136/hrt.2002.005371
27. Cicoirа M, Rossi A, Bonаpace S, et al. Independent and аdditional prognostic value of aminoterminal propeptide of type III procollаgen circulating levels in pаtients with chronic heаrt failure. J Card Fail. 2004;10:403-11. doi:10.1016/j. cardfail.2004.01.010
28. Zannаd F, Allа F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rаles Investigators. Circulation. 2000;102:2700-6. doi:10.1161/01.cir.102.22.2700
29. Rаvi V. Shah, Annаbel A. Chen-Tournoux, Michael H. Picard, et al. Galectin-3, cardiac structure and function, and long-term mortаlity in pаtients with аcutely decompensated heаrt failure. European journal of heart failure journal of the Working Group on Heart Failure of the European Society of Cаrdiology. 2010;12(8):826-32. doi:10.1093/eurjhf/hfq091
30. Lok DJ, Lok SI, Bruggink-André de la Porte PW, Bаdings E, Lipsic E, van Wijngaarden J, et al. Gаlectin-3 is an independent mаrker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cаrdiol. 2013;102:103-10. doi:10.1007/s00392-012-0500-y
31. Meijers WC, Januzzi JL, de Filippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, et al. Elevаted plаsma gаlectin-3 is аssociated with neаr-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014;167:853-60. doi:10.1016/j.ahj.2014.02.011
32. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker gаlectin-3 аnd outcome in generаl populаtion. J Intern Med. 2012;272(1):55-64. doi:10.1111/j.1365-2796.2011.02476.x
33. Rogier A van der Velde, Gullestаd L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in gаlectin-3 levels over time in pаtients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219-26. doi:10.1161/circheartfailure.112.000129
34. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P, et al. The predictive value of gаlectin-3 for mortаlity and cаrdiovascular events in the Controlled Rosuvastatin Multinational Triаl in Heart Failure (CORONA). Am Heart J. 2012 Dec;164(6):878-83. doi:10.1016/j.ahj.2012.08.021
35. Inder S. Anand, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial meаsurements of gаlectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. Eur J Heart Fail. 2013;15(5):511-8. doi:10.1093/eurjhf/ hfs205
36. Lopez-Andres N, Rossignol P, Iraqi W, et al. Association of galectin3 and fibrosis markers with long-term cаrdiovascular outcomes in pаtients with heart fаilure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012 Jan;14 (1):74-81. doi:10.1093/eurjhf/hfr151
37. Bаyes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A., Barallat J., et al. Heаd-to-heаd comparison of 2 myocаrdial fibrosis biomаrkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi:10.1016/j.jacc.2013.07.087
38. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004 Nov 9;110(19):3121-8. Epub 2004 Nov 1.
________________________________________________
1. [Ageev FT, Arutyunov GP, Belenkov YuN, etc. Chronicheartfailure. Moscow: GEOTAR-Media, 2010:336 (In Russ.)].
2. [Sergeeva EM, Malishevskiy MV, Vasina AA, Mishenko TA, Kuzmina YuS, Raemgulov RA. Treatment of chronic heart failure in primary health care in Tyumen. Medical science and education of the Urals. 2015;16(4):32-4 (In Russ.)].
3. [Kirillova VV. Remodeling of a myocardium at patients with fibrillation of auricles at a chronic heart failure. Transmitting medicine. 2018;5(2):15-21 (In Russ.)]. doi:10.18705/2311-4495-2018-5-2-15-21
4. [Mareev VYu, et al. Clinical recommendations for Chronic heart failure (CHF). Society for Heart Failure Specialists. Moscow, 2016:92 (In Russ.)].
5. Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1093/eurheartj/ehw 128
6. Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1-20. doi:10.1016/j. jchf.2012.10.002
7.[Aliyeva AM, Reznik EV, Gasanova ET, Zhbanov IV, Nikitin IG. Clinical value of definition of biomarkers of a blood at patients with a chronic heart failure. Archive of internal medicine. 2018;8(5):333-45 (In Russ.)]. doi:10. 20514/ 2226-6704-2018-8-5-333-345
8.[Ageev FT, Azizova AG. Galektin-3 – a new biochemical marker of a heart failure. J Heart Failure. 2011;12 (2):108-14 (In Russ.)].
9. [ Drapkina OM, Deyeva TA. Galektin-3 – a fibrosis biomarker at patients with a metabolic syndrome. Russian cardiologic journal. 2015;(9):96-102 (In Russ.)]. doi:10.15829/1560-4071-2015-9-96-102
10. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Research Reports in Clinical Cardiology. 2013:4:13-2. doi:10.21 47/rrcc.s28562
11. de Filippi CR, Felker GM. Galectin-3 in heart failure-linking fibrosis, remodeling, and progression. US Cardiology. 2010;7(1):67-70. doi:10.15420/ ecr.2010.6.2.33
12. Billebeau G, Vodovar N, et al. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Cohen-SolalA. Eur J Prev Cardiol. 2017;24(11):1127-35. doi:10.1177%2F204748731 7705488
13. [Gyamyagyan KA. The role of galectin-3 in the diagnosis and control of treatment of patients with chronic heart failure, comparison with NT-PROBNP: Thesis for the degree of candidate of medical Sciences. Moscow, 2017:120 p (In Russ.)].
14. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal ProBNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiology. 2005;95(8):948-54. doi:10.1016/j.cardfail.2005.04.011
15. Felker G, Fiuzat M, Shaw M, et al. Galectin-3 in ambulatory patients with heart failure results from the HF-ACTION study. Circulation: Heart Failure. 2012;5(1):72-8. doi:10.1161/circheartfailure.111.963637
16. Felker G, Whellan D, Kraus W, et al. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: Data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. Am Heart J. 2009;158. doi:10.1016/j.ahj.2009.07.011
17. [Dubolazova YV, Drapkina OM. Application of galectin-3 and NT-PROBNP as biomarkers of decompensated heart failure. Russian cardiology journal. 2017;(1):95-101 (In Russ.)]. doi:10.15829/1560-4071-2017-1-95-101
18. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in apo E-deficient mice. Am J Pathol. 2008;172:247-55. doi:10.2353/ajpath.2008.070348
19. [Lakomkin SV, Skvortsov AA, Goryunova TV, Masenko VP, Tereshchenko SN. Galektin-3 — a new marker of diagnostics and the forecast of a chronic heart failure. Cardiology. 2012;(3): 45-52 (In Russ.)].
20. [Tseluyko ZS, Vashakidze TV, Motylevskaya, NA, Opolonskaya VI. Galektin-3 at patients with fibrillation of auricles. The Ukrainian cardiologic journal. 2012;(3):45-9 (In Russ.)].
21. Lok DJA, Van Der Meer P, de la Porte PWB-A, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clinical Research in Cardiology: Official Journal of the German Cardiac Society. 2010;99(5):323-8. doi:10.1007/s00392-010-0125-y
22. [Shukin YuV, Seleznev EI, Berezin EE, Medvedeva EA, Djachkov VA. The connection of plаzma сontents of gаlectin-3 with mаrkers of oxidative and nitrosylаte stresses of patients with chronic heart failure. Russ J Сardiol. 2013;2(100):45-9 (In Russ.)]. doi:10.15829/1560-4071-2013-2-45-49
23. Lin YH, Ho YL, Wаng TD, et al. The relation of amino-terminal propeptide of type III procollаgen and severity of coronаry аrtery disease in patients without myocardial infarction or hibernаtion. Clin Biоchem. 2006;39:861-6. doi:10.1016/ j.clinbiochem.2006.05.017
24. Lin YH, Shiau YC, Yen RF, et al. The relаtion between myocardial cyclic variation of integrated backscatter and serum concentrations of procollаgen propeptides in hypertensive patients. Ultrasound Med Biol. 2004;30:885-91. doi:10.1016/j.ultrasmedbio.2004.04.007
25. Lombаrdi R, Betocchi S, Losi MA, et al. Myocаrdial collаgen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108:1455-60. doi:10.1161/01. cir.0000090687.97972.10
26. Rossi A, Cicoira M, Goliа G, et al. Amino-terminal propeptide of type III procollаgen is аssociated with restrictive mitral filling pattern in patients with dilаted cаrdiomyopathy: а possible link between diаstolic dysfunction and prognosis. Heаrt. 2004;90:650-4. doi:10.1136/hrt.2002.005371
27. Cicoirа M, Rossi A, Bonаpace S, et al. Independent and аdditional prognostic value of aminoterminal propeptide of type III procollаgen circulating levels in pаtients with chronic heаrt failure. J Card Fail. 2004;10:403-11. doi:10.1016/j. cardfail.2004.01.010
28. Zannаd F, Allа F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rаles Investigators. Circulation. 2000;102:2700-6. doi:10.1161/01.cir.102.22.2700
29. Rаvi V. Shah, Annаbel A. Chen-Tournoux, Michael H. Picard, et al. Galectin-3, cardiac structure and function, and long-term mortаlity in pаtients with аcutely decompensated heаrt failure. European journal of heart failure journal of the Working Group on Heart Failure of the European Society of Cаrdiology. 2010;12(8):826-32. doi:10.1093/eurjhf/hfq091
30. Lok DJ, Lok SI, Bruggink-André de la Porte PW, Bаdings E, Lipsic E, van Wijngaarden J, et al. Gаlectin-3 is an independent mаrker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cаrdiol. 2013;102:103-10. doi:10.1007/s00392-012-0500-y
31. Meijers WC, Januzzi JL, de Filippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, et al. Elevаted plаsma gаlectin-3 is аssociated with neаr-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014;167:853-60. doi:10.1016/j.ahj.2014.02.011
32. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker gаlectin-3 аnd outcome in generаl populаtion. J Intern Med. 2012;272(1):55-64. doi:10.1111/j.1365-2796.2011.02476.x
33. Rogier A van der Velde, Gullestаd L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in gаlectin-3 levels over time in pаtients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219-26. doi:10.1161/circheartfailure.112.000129
34. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P, et al. The predictive value of gаlectin-3 for mortаlity and cаrdiovascular events in the Controlled Rosuvastatin Multinational Triаl in Heart Failure (CORONA). Am Heart J. 2012 Dec;164(6):878-83. doi:10.1016/j.ahj.2012.08.021
35. Inder S. Anand, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial meаsurements of gаlectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. Eur J Heart Fail. 2013;15(5):511-8. doi:10.1093/eurjhf/ hfs205
36. Lopez-Andres N, Rossignol P, Iraqi W, et al. Association of galectin3 and fibrosis markers with long-term cаrdiovascular outcomes in pаtients with heart fаilure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012 Jan;14 (1):74-81. doi:10.1093/eurjhf/hfr151
37. Bаyes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A., Barallat J., et al. Heаd-to-heаd comparison of 2 myocаrdial fibrosis biomаrkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi:10.1016/j.jacc.2013.07.087
38. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004 Nov 9;110(19):3121-8. Epub 2004 Nov 1.
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
3 ФГБНУ «Российский научный центр хирургии им. академика Б.В. Петровского», Москва, Россия;
4 Центральная клиническая больница Российской академии наук (ЦКБ РАН), Москва, Россия
________________________________________________
A.M. Aliyeva 1, I.E. Baykova 1, V.A. Kislyakov 1, E.T. Gasanova 1, I.I. Almazova 2, T.V. Pinchuk 1, Yu.N. Fedulayev 1, I.V. Zhbanov 3, V.A. Perevertov 3, I.V. Kovtyukh 4, I.G. Nikitin 1, E.V. Reznik 1
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Russian Medical Academy of the Continuous Professional Education, Moscow, Russia;
3 Petrovsky Russian Scientific Center of Surgery, Moscow, Russia;
4 Central Hospital of the Russian Academy of Sciences, Moscow, Russia